S&P 500   4,246.80 (+0.87%)
DOW   33,571.86 (+0.79%)
QQQ   328.58 (+0.81%)
AAPL   170.22 (+0.58%)
MSFT   289.03 (-0.04%)
META   181.20 (+1.60%)
GOOGL   121.03 (+1.11%)
AMZN   143.48 (+0.55%)
TSLA   882.56 (-0.06%)
NVDA   184.63 (+2.02%)
NIO   21.42 (+6.83%)
BABA   96.16 (+4.04%)
AMD   101.08 (+2.05%)
MU   63.18 (+2.90%)
T   18.13 (+0.67%)
CGC   3.44 (+4.56%)
GE   78.34 (+1.56%)
F   15.75 (+1.61%)
DIS   121.91 (+8.43%)
AMC   25.05 (+5.83%)
PYPL   101.00 (+2.11%)
PFE   48.47 (-2.96%)
NFLX   247.90 (+1.55%)
S&P 500   4,246.80 (+0.87%)
DOW   33,571.86 (+0.79%)
QQQ   328.58 (+0.81%)
AAPL   170.22 (+0.58%)
MSFT   289.03 (-0.04%)
META   181.20 (+1.60%)
GOOGL   121.03 (+1.11%)
AMZN   143.48 (+0.55%)
TSLA   882.56 (-0.06%)
NVDA   184.63 (+2.02%)
NIO   21.42 (+6.83%)
BABA   96.16 (+4.04%)
AMD   101.08 (+2.05%)
MU   63.18 (+2.90%)
T   18.13 (+0.67%)
CGC   3.44 (+4.56%)
GE   78.34 (+1.56%)
F   15.75 (+1.61%)
DIS   121.91 (+8.43%)
AMC   25.05 (+5.83%)
PYPL   101.00 (+2.11%)
PFE   48.47 (-2.96%)
NFLX   247.90 (+1.55%)
S&P 500   4,246.80 (+0.87%)
DOW   33,571.86 (+0.79%)
QQQ   328.58 (+0.81%)
AAPL   170.22 (+0.58%)
MSFT   289.03 (-0.04%)
META   181.20 (+1.60%)
GOOGL   121.03 (+1.11%)
AMZN   143.48 (+0.55%)
TSLA   882.56 (-0.06%)
NVDA   184.63 (+2.02%)
NIO   21.42 (+6.83%)
BABA   96.16 (+4.04%)
AMD   101.08 (+2.05%)
MU   63.18 (+2.90%)
T   18.13 (+0.67%)
CGC   3.44 (+4.56%)
GE   78.34 (+1.56%)
F   15.75 (+1.61%)
DIS   121.91 (+8.43%)
AMC   25.05 (+5.83%)
PYPL   101.00 (+2.11%)
PFE   48.47 (-2.96%)
NFLX   247.90 (+1.55%)
S&P 500   4,246.80 (+0.87%)
DOW   33,571.86 (+0.79%)
QQQ   328.58 (+0.81%)
AAPL   170.22 (+0.58%)
MSFT   289.03 (-0.04%)
META   181.20 (+1.60%)
GOOGL   121.03 (+1.11%)
AMZN   143.48 (+0.55%)
TSLA   882.56 (-0.06%)
NVDA   184.63 (+2.02%)
NIO   21.42 (+6.83%)
BABA   96.16 (+4.04%)
AMD   101.08 (+2.05%)
MU   63.18 (+2.90%)
T   18.13 (+0.67%)
CGC   3.44 (+4.56%)
GE   78.34 (+1.56%)
F   15.75 (+1.61%)
DIS   121.91 (+8.43%)
AMC   25.05 (+5.83%)
PYPL   101.00 (+2.11%)
PFE   48.47 (-2.96%)
NFLX   247.90 (+1.55%)
NASDAQ:ABMD

Abiomed - ABMD Stock Forecast, Price & News

$296.77
+3.43 (+1.17%)
(As of 08/11/2022 09:51 AM ET)
Add
Compare
Today's Range
$293.21
$297.19
50-Day Range
$224.73
$301.46
52-Week Range
$219.85
$379.30
Volume
1,519 shs
Average Volume
255,015 shs
Market Capitalization
$13.54 billion
P/E Ratio
62.61
Dividend Yield
N/A
Price Target
$311.25

Abiomed MarketRank™ Forecast

Analyst Rating
Hold
1.67 Rating Score
Upside/​Downside
6.1% Upside
$311.25 Price Target
Short Interest
Healthy
3.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.79
Upright™ Environmental Score
News Sentiment
0.25mentions of Abiomed in the last 14 days
Based on 34 Articles This Week
Insider Trading
Selling Shares
$816,020 Sold Last Quarter
Proj. Earnings Growth
18.18%
From $4.73 to $5.59 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

451st out of 1,108 stocks

Surgical & Medical Instruments Industry

44th out of 112 stocks

ABMD stock logo

About Abiomed (NASDAQ:ABMD) Stock

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ABMD. Morgan Stanley lowered their price objective on Abiomed from $275.00 to $235.00 and set an "underweight" rating for the company in a research note on Friday, July 15th. Deutsche Bank Aktiengesellschaft lowered their price objective on Abiomed from $410.00 to $355.00 in a research note on Thursday, July 21st. Finally, StockNews.com lowered Abiomed from a "buy" rating to a "hold" rating in a research note on Friday, July 1st.

Abiomed Trading Up 4.1 %

Shares of ABMD Stock traded up $11.63 on Wednesday, reaching $293.34. 192,356 shares of the company's stock were exchanged, compared to its average volume of 332,820. Abiomed has a 52 week low of $219.85 and a 52 week high of $379.30. The stock has a market capitalization of $13.38 billion, a PE ratio of 61.89 and a beta of 1.35. The company's fifty day simple moving average is $263.24 and its 200 day simple moving average is $282.90.

Abiomed (NASDAQ:ABMD - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The medical equipment provider reported $1.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.06 by $0.19. Abiomed had a return on equity of 14.33% and a net margin of 20.60%. The firm had revenue of $277.15 million during the quarter, compared to analyst estimates of $276.46 million. During the same period last year, the company earned $1.10 EPS. Abiomed's quarterly revenue was up 9.7% compared to the same quarter last year. As a group, sell-side analysts predict that Abiomed will post 4.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Abiomed news, Director Martin P. Sutter sold 2,000 shares of the firm's stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $258.01, for a total transaction of $516,020.00. Following the transaction, the director now directly owns 128,390 shares in the company, valued at approximately $33,125,903.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Todd A. Trapp sold 1,000 shares of Abiomed stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $300.00, for a total value of $300,000.00. Following the transaction, the chief financial officer now directly owns 16,927 shares in the company, valued at approximately $5,078,100. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Martin P. Sutter sold 2,000 shares of Abiomed stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $258.01, for a total value of $516,020.00. Following the completion of the transaction, the director now owns 128,390 shares in the company, valued at $33,125,903.90. The disclosure for this sale can be found here. 2.50% of the stock is currently owned by company insiders.

Receive ABMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abiomed and its competitors with MarketBeat's FREE daily newsletter.

ABMD Stock News Headlines

Why Shares of Abiomed Rose 18.4% in July
Abiomed, Inc. (NASDAQ:ABMD) CFO Sells $300,000.00 in Stock
Abiomed Inc. Q1 Earnings Summary
Abiomed (ABMD) Q1 Earnings Top Estimates, Margins Down
Abiomed (ABMD) Q1 Earnings Top Estimates
Abiomed FQ1 2023 Earnings Preview - Seeking Alpha
Abiomed (ABMD) Set to Announce Earnings on Thursday
See More Headlines
Receive ABMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abiomed and its competitors with MarketBeat's FREE daily newsletter.

ABMD Company Calendar

Last Earnings
8/04/2022
Today
8/11/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ABMD
CUSIP
00365410
Employees
2,003
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$311.25
High Stock Price Forecast
$355.00
Low Stock Price Forecast
$235.00
Forecasted Upside/Downside
+4.9%
Consensus Rating
Hold
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

Net Income
$136.51 million
Pretax Margin
25.53%

Debt

Sales & Book Value

Annual Sales
$1.03 billion
Cash Flow
$5.36 per share
Book Value
$33.67 per share

Miscellaneous

Free Float
44,485,000
Market Cap
$13.54 billion
Optionable
Optionable
Beta
1.35

Social Links















ABMD Stock - Frequently Asked Questions

Should I buy or sell Abiomed stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ABMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View ABMD analyst ratings
or view top-rated stocks.

What is Abiomed's stock price forecast for 2022?

3 Wall Street research analysts have issued 12-month price targets for Abiomed's shares. Their ABMD share price forecasts range from $235.00 to $355.00. On average, they anticipate the company's stock price to reach $311.25 in the next year. This suggests a possible upside of 6.1% from the stock's current price.
View analysts price targets for ABMD
or view top-rated stocks among Wall Street analysts.

How have ABMD shares performed in 2022?

Abiomed's stock was trading at $359.17 at the start of the year. Since then, ABMD stock has decreased by 18.3% and is now trading at $293.34.
View the best growth stocks for 2022 here
.

When is Abiomed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our ABMD earnings forecast
.

How were Abiomed's earnings last quarter?

Abiomed, Inc. (NASDAQ:ABMD) issued its quarterly earnings results on Thursday, August, 4th. The medical equipment provider reported $1.25 earnings per share for the quarter, topping the consensus estimate of $1.06 by $0.19. The medical equipment provider earned $277.15 million during the quarter, compared to the consensus estimate of $276.46 million. Abiomed had a trailing twelve-month return on equity of 14.33% and a net margin of 20.60%. The company's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.10 earnings per share.
Read the conference call transcript
.

What guidance has Abiomed issued on next quarter's earnings?

Abiomed issued an update on its FY 2023 earnings guidance on Thursday, August, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.13 billion-$1.17 billion, compared to the consensus revenue estimate of $1.18 billion.

What is Michael R. Minogue's approval rating as Abiomed's CEO?

96 employees have rated Abiomed Chief Executive Officer Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among the company's employees.

What other stocks do shareholders of Abiomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Block (SQ), Netflix (NFLX), Adobe (ADBE) and Salesforce (CRM).

What is Abiomed's stock symbol?

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Who are Abiomed's major shareholders?

Abiomed's stock is owned by a variety of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (8.13%), William Blair Investment Management LLC (2.14%), Allspring Global Investments Holdings LLC (0.55%), Swiss National Bank (0.43%), Scout Investments Inc. (0.43%) and Country Trust Bank (0.33%). Insiders that own company stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue, Michael R Minogue, Paul Thomas and Todd A Trapp.
View institutional ownership trends
.

How do I buy shares of Abiomed?

Shares of ABMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abiomed's stock price today?

One share of ABMD stock can currently be purchased for approximately $293.34.

How much money does Abiomed make?

Abiomed (NASDAQ:ABMD) has a market capitalization of $13.38 billion and generates $1.03 billion in revenue each year. The medical equipment provider earns $136.51 million in net income (profit) each year or $4.74 on an earnings per share basis.

How many employees does Abiomed have?

The company employs 2,003 workers across the globe.

Does Abiomed have any subsidiaries?

The following companies are subsidiares of Abiomed: ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, ABIOMED Limited, ABIOMED R&D, ABIOMED SARL, ABIOMED Singapore Pte. Ltd, AIS GmbH Aachen Innovative Solutions, ECP Entwicklungsgesellschaft mbH, and Impella Cardiosystems.
Read More

When was Abiomed founded?

Abiomed was founded in 1981.

How can I contact Abiomed?

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The official website for the company is www.abiomed.com. The medical equipment provider can be reached via phone at (978) 646-1400, via email at ir@abiomed.com, or via fax at 978-777-8411.

This page (NASDAQ:ABMD) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.